When artificial intelligence meets PD-1/PD-L1 inhibitors: Population screening, response prediction and efficacy evaluation.
Comput Biol Med
; 145: 105499, 2022 06.
Article
em En
| MEDLINE
| ID: mdl-35439641
ABSTRACT
Programmed cell death protein-1 (PD-1) and its ligand (programmed death ligand 1, PD-L1) inhibitors, as the rising stars of immunotherapy, have been widely used in clinical practice, and the corresponding population screening, response prediction and efficacy evaluation have become increasingly important in clinic. Artificial Intelligence (AI) can help us uncover effective information from clinical data such as medical history, images, laboratory results, sequencing data, etc., which can help us solve above problems and enrich the methodology of clinical research. In this way, AI researches related to PD-1/PD-L1 inhibitors have been emerging. Based on an introduction of AI fundamentals in medicine, this review systematically summarizes the existing AI studies related to PD-1/PD-L1 immunotherapy in three aspects population screening, response prediction and efficacy evaluation, and briefly outlooks the development direction of AI studies related to PD-1/PD-L1 inhibitors.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Carcinoma Pulmonar de Células não Pequenas
/
Neoplasias Pulmonares
Tipo de estudo:
Diagnostic_studies
/
Prognostic_studies
/
Risk_factors_studies
/
Screening_studies
Limite:
Animals
/
Humans
Idioma:
En
Revista:
Comput Biol Med
Ano de publicação:
2022
Tipo de documento:
Article
País de afiliação:
China